HEARx close to eliminating debt:
This article was originally published in Clinica
HEARx, the US hearing care network, has reached agreement with several medical device companies which it says will eliminate its $1.2 million debt over four years. The debt will be reduced if the organisation reaches certain goals stipulated in contracts with the companies.
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.